Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors α-1 and β-1  by Gierach, Izabela et al.
FEBS Open Bio 2 (2012) 247–253
journa l homepage: www.e lsev ier .com/ locate / febsopenbioBacterial biosensors for screening isoform-selective ligands for human thyroid
receptors α-1 and β-1Izabela Gieracha, Jingjing Lia,b, Wan-Yi Wua, Gary J. Groverc, David W. Woodb,*
aDepartment of Chemical Engineering, Princeton University, Princeton, NJ 08544,USA
bDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA
cDepartment of Physiology and Biophysics, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA
a r t i c l e i n f o
Article history:
Received 17 April 2012
Received in revised form 11 July 2012
Accepted 8 August 2012
Keywords:
Bacterial biosensor
Thyroid receptor
Thyroid receptor subtype-selectivity
Drug screening
Inteins
a b s t r a c t
Subtype-selective thyromimetics have potential as new pharmaceuticals for the prevention or treat-
ment of heart disease, high LDL cholesterol and obesity, but there are only a fewmethods that can detect
agonistic behavior of TR-active compounds. Among these are the rat pituitary GH3 cell assay and tran-
scriptional activation assays in engineered yeast and mammalian cells. We report the construction and
validation of a newly designed TRα-1 bacterial biosensor, which indicates the presence of thyroid active
compounds through their impacts on the growth of an engineered Escherichia coli strain in a simple
deﬁned medium. This biosensor couples the conﬁguration of a hormone receptor ligand-binding do-
main to the activity of a thymidylate synthase reporter enzyme through an engineered allosteric fusion
protein. The result is a hormone-dependent growth phenotype in the expressing E. coli cells. This sen-
sor can be combined with our previously published TRβ-1 biosensor to detect potentially therapeutic
subtype-selective compounds such as GC-1 and KB-141. To demonstrate this capability, we determined
the half-maximal effective concentration (EC50) for the compounds T3, Triac, GC-1 and KB-141 using our
biosensors, and determined their relative potency in each biosensor strain. Our results are similar to
those reported bymammalian cell reporter gene assays, conﬁrming theutility of our assay in identifying
TR subtype-selective therapeutics. This biosensor thus provides a high-throughput, receptor-speciﬁc,
and economical method (less than US$ 0.10 per well at laboratory scale) for identifying important
therapeutics against these targets.
c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Thyroid hormones play an essential role in the physiological regu-
lation of different tissues, aswell as overallmetabolic rate, cholesterol
level and heart rate. The targets of thyroid hormones are the thyroid
receptors (TRs), which belong to the nuclear receptor (NR) superfam-
ily. Two major classes of TR receptors are known, TRα and TRβ, each
of which is expressed in multiple isoforms (TRα-1, TRα-2, TRβ-1,
TRβ-2). The thyroid receptors TRα-1 and TRβ-1 each contain six do-
mains (A–F), similar to estrogen receptors α and β and other NRs.
The DNA binding (C), hinge (D) and ligand binding (E) domains in the
TRα-1 and TRβ-1 isoforms are respectively 88%, 71% and 86% iden-
tical, while no homology has been observed in activation function-1Database: Human TRα-1 and TRα-2 sequence data are available in the GenBank
database under the accession numbers BC008851.2 and NM 003250, respectively.
Abbreviations: pMIT::TR, plasmid Maltose Binding Protein-Intein-Thymidylate
Synthase, with inserted TR LBD; MBP, maltose-binding protein; N-Mtu, the ﬁrst 110
amino acid residues of the Mtu RecA intein; C-Mtu, the last 58 amino acid residues of
the Mtu RecA intein; TS, T4 thymidylate synthase enzyme
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http://dx.doi.org/10.1016/j.fob.2012.08.002domain (A/B; AF1), which are isoform speciﬁc. The domains E/F effect
transcription activation upon ligand binding and receptor dimeriza-
tion, while the E domain contains activation function-2 (AF-2). The TR
isoforms are expressed at different levels in different tissues. For ex-
ample, the TRα-1 isoform is dominant in heart (70%),while the TRβ-1
isoform is dominant in the liver (80%), suggesting that these recep-
tors may be important targets for subtype-selective thyroid hormone
receptor modulator (STRM) therapeutics [1–3].
Thyroid hormone receptors are essential for proper infant central
nervous system (CNS) development, and their production is regulated
by the hypothalamic-pituitary-thyroid feedback system. Among non-
isoform selective TR-binding compounds, T3 is the native hormone in
the human body, and is produced by follicular cells of the thyroid
gland [1,4]. These cells accumulate iodide from plasma through their
membranes and use it for the production of secreted human thyroid
hormones. A deﬁciency or excess of these hormones, referred to as
hypothyroidism or hyperthyroidism, may lead to myxedema coma,
cretinism, and other serious disorders.B.V. Open access under CC BY-NC-ND license.
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Several therapeutic strategies have been devised to treat thyroid-
related disorders. For example, thioureylenes can be used in hyper-
thyroidism to inhibit thyroid hormone production, as well as the con-
version of the less active 3,5,3′,5′-tetraiodo-l-thyronine (thyroxine;
T4) to more active 3,5
′,3-triiodo-l-thyronine (triiodothyronine; T3).
Direct administration of T3 is also used to treat hypothyroidism and
associatedobesity.Unfortunately, theuseof T3 is limitedby its agonist
activity against both TR isoforms, and resulting cardiovascular side ef-
fects such as tachycardia. The presence of additional tissue-speciﬁc
side effects, arising from varying TR isoform levels in differing tis-
sues, suggests that it may be desirable to develop subtype-selective
TR modulators (STRMs). Work in this area led to the ﬁnding that a
single amino acid residue difference (Ser277→Asn331) in the ligand-
binding pockets of TRα and TRβ have a direct effect on the binding
selectivity of potential STRMs [5,6]. Triiodothyroacetic acid (Triac) has
been found to be TRβ selective as well [7], but the exact mechanism
of its selectivity is not well understood. Martinez et al. suggested that
the observed 2- to 3-fold selectivity of Triac for TRβ is connected to
conformational changes in Triac itself, possibly caused by the high
ﬂexibility of its carboxylate group [8].
These studies have facilitated the recent development of several
potentially therapeutic isoform-selective TRβ agonists, which in-
clude Sobetirome (GC-1), which lowers LDL cholesterol level with no
effect on the cardiovascular system, as well as Eprotirome (KB-2115)
andMB07811 for dislipidemia [9–11]. In addition to these, several TR
antagonists have been developed for potential therapeutic uses, such
as 1–850, DIBRT (low potency), NH-3 (high potency), and the partial
antagonist GC-14 (low potency) [12–14]. Developing an ideal STRM
is challenging. Several TRβ selective agonists, such as Axitirome and
KB-141, have been discontinued during clinical development due to
unexpected side effects [1,2,15,16]. The desire for isoform-selective
compounds, coupledwith the difﬁculties associated with their devel-
opment, provides a strong impetus for the creation of new screening
methods for isotype-selective TR modulators.
The detection of various thyromimetic compounds is commonly
analyzed by using a growth hormone 3 (GH3) cell assay [17], as
well as various protein microarray methods [18], in vitro time-
resolved Fluorescence Resonance Energy Transfer (TR-FRET) assays
(LanthaScreenTM; Invitrogen, Carlsbad, CA), and a number of tran-
scriptional activation assays [1,12,19–21]. The main disadvantage of
the GH3 cell assay compared to other biosensor assays is that it does
not report receptor isoform-speciﬁcity since the cells contain TRβ-1,
TRα-1 and TRα-2 receptors [22]. The cells are also derived from rat
and not from human. Mammalian or yeast transcriptional activation
assays rely on reporter proteins such as luciferase orβ-galactosidase,
where a TR-responsive promoter, engineered into the host strain,
drives their expression.
Several additional strategies for detecting and identifying
hormone-like compounds rely on fusions between the hormone re-
ceptor ligand-binding domain (LBD) and various other functional pro-
teins in yeast and mammalian cells [23]. One group of these includes
direct end-to-end or insertional fusions of LBDs to functional en-
zymes, where the binding of a ligand by the LBD will directly activate
the fused reporter protein [24–26]. A second group involves fusion of
the NR LBD to a GAL4 DNA-binding domain to generate a highly sen-
sitive transcriptional assay for ligand function [27,28]. Both of these
assay types are highly effective and allow generation of new assays by
simple LBD swapping. Strengths of these assays include their ability
to function in yeast and mammalian cells, high sensitivity to ligands,
and the lack of requirement for NR-speciﬁc cofactors and coactiva-
tors. These strengths have led a few of these assays to be commercial-
ized, including the HEK 293T cell-based GeneBLAzer beta-Lactamase
reporter system (Invitrogen, Carlsbad, CA) for detection of agonists
and antagonists against a variety of available NRs. One drawback of
these assays is the potential formisclassiﬁcation of the tested ligands.
This can arise from the cellular context of a given assay (e.g., yeastversus human tissue), which may exhibit differences in coactivator
levels, membrane transport characteristics, and genetic background
[29–32]. Additional artifacts can arise from the use of isolated NR
LBDs in fusion to the non-native reporter protein domains, which can
misreport the relative activities of antagonists and agonists. A ﬁnal,
yet signiﬁcant drawback is the cost of some of these assays, which
can approach one thousand U.S. dollars per 384-well plate in the case
of the GeneBLAzer reporter system mentioned above.
The biosensor assay presented here is an Escherichia coli (E. coli)
growth-based technique. In this assay, the conformation of the TR
LBD is linked to the activity of a thymidylate synthase (TS) reporter
enzyme through an engineered allosteric biosensor protein. The en-
gineered sensor protein consists of the TS reporter enzyme linked to
an intein splicing domain and maltose binding protein. In previous
work, we have shown that the activity of the TS reporter is repressed
when it is in fusion to the intein splicing domain, likely due to steric
blockage of TS dimerization [33]. In the engineered biosensor protein,
the NHR LBD is inserted into the splicing domain, which appears to
stabilize the correct fold of the LBDwhile simultaneously blocking TS
dimerization. Our hypothesis is that the repositioning of helix 12 of
the TR LBD upon ligand binding induces a conformational change in
the intein domain, which leads to dose-dependent activation of the
TS domain [34].
Since TS activity is required for E. coli cell growth, the conﬁgu-
ration of the TR LBD is reﬂected in the TS phenotype of the cells
expressing the biosensor protein. The TS phenotype can be observed
and quantiﬁed using positive selection in a deﬁned liquid growth
medium that lacks thymine (-Thy medium), or negative selection
using -Thy medium supplemented with thymine and trimethoprim
(TTM medium) [35]. Thus, an important aspect of the screen is its
ability to conﬁrm the effects of a given ligand on LBD-dependent TS
activity through themirror imagephenotypes observedwith -Thy and
TTMmedia. In this case, a general growth effect (e.g., nutritional affect
or toxicity)mayproduce a positive growthphenotype in onemedium,
butwould fail to produce themirror image phenotype in the alternate
growthmedium.Generation of dose-response curves in -Thy andTTM
liquid media permits an estimate of the relative binding afﬁnities of
test compounds for the TR LBD targets, thus providing a rapid means
for detecting and characterizing isoform-selective ligands. Because
this assay relies on simple E. coli growth in liquid medium, it is non-
radioactive, economical and simple to use. Further, only the LBDof the
desired NR is cloned into the E. coli cells, which greatly simpliﬁes the
generation of speciﬁc NR biosensors. In this work, we demonstrate
the capability of the system to readily detect several TR ligands (Fig.
1), and to identify subtype-selective thyromimetic ligands.2. Materials and methods
2.1. Ligands
Compounds were acquired from the following sources: E2 (17-
β-estradiol) and Triac (3,3′,5-triiodothyroacetic acid, 95%) from
Sigma (Saint Louis, MO), as well as T3 (3,3
′,5-triiodo-l-thyronine
sodium salt hydrate, 95%) from Aldrich Chemical (Milwaukee, WI).
The selective TRβ agonists, GC-1 (3,5-dimethyl-4-(4′-hydroxy-3′-
isopropylbenzyl)-phenoxy acetic acid) was synthesized by Thomas
S. Scanlan’s Laboratory (Oregon Health and Sciences University, Port-
land, OR, USA). The GC-1 and KB-141 (3,5-dichloro-4-(4-hydroxy-3-
isopropylphenoxy) phenylacetic acid) were provided as a gift from
Dr. Gary Grover (UMDNJ, NJ). The structures of the compounds are
included in Fig. 1.
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Fig. 1. Structures included in the study: T3 [CAS: 6893–02-3]; Triac [CAS: 51–24-1];
KB-141 [CAS: 219691–94-8]; GC-1 [CAS: 211110–63-3]; 17-β-estradiol (E2) [CAS:
50–28-2].
Fig. 2. Schematic representation of the engineered chimeric biosensor proteins con-
taining the ΔI mini-intein and human TRα-1 or TRβ-1 LBDs. Abbreviations: Ptac* =
artiﬁcial tac promoter, the asterisk (*) denotes the G to A base-pair mutation required
for hormone-dependent phenotypes; MBP = maltose-binding protein; N-Mtu = the
ﬁrst 110 amino acid residues of the Mtu RecA intein; C-Mtu = the last 58 amino acid
residues of theMtuRecA intein; TRα-1=human thyroid hormone receptorα-1 ligand-
binding domain; TRβ-1 = human thyroid hormone receptor β-1 ligand-binding do-
main; TS = T4 thymidylate synthase enzyme. The boundaries of the TR LBDs sequence
are indicated by arrows above each diagram.2.2. Construction of the fused chimeric protein containing human
thyroid receptors
A TRα-2 gene fragment, comprising bases 3030–3697 of the plas-
mid pCMV6-XL5 hTRα-2 (GenBank:NM 003250, GI:40806158; Ori-
Gene Technologies; Rockville, MD), was fused to an additional 110
bases of the TRα-1 ligand-bindingdomain to form theputative TRα-1
LBD. The putative TRα-1 LBD contains bases 1091–1867 (correspond-
ing to TRα-1 ORF amino acids E149 to D407) of the full length TRα
cDNA (GenBank:BC008851.2, GI:39644841) [36]. The constructed
TRα-1 was inserted into the ΔI mini intein, comprised of the ﬁrst
110 residues and ﬁnal 58 residues of the full-length Mycobacterium
tuberculosis RecA intein [37]. The insertion was carried out using
silently generated NheI and SacII restriction sites within the mini-
intein segments, to create pMIT::TRα-1, where pMIT stands for: plas-
mid Maltose Binding Protein-Intein-Thymidylate Synthase, with in-
serted TRα-1 LBD (Fig. 2).
The construction of pMIT::TRβ-1 was based on our previously
reported pMIT::TR* biosensor plasmid [33] by simple replacement
of TRα-1 LBD in pMIT::TRα-1 by the TRβ-1 LBD (corresponding to
TRβ-1 ORF amino acids E203 to D461) to assure identical plasmid
construction. Its construction also relied on the silent NheI and SacII
restriction sites with the N- and C-terminal segments of the mini-
intein (see Supplemental Materials, Table S1 for primer and TR LBDsequences).
2.3. Phenotype determination
The TS-deﬁcient E. coli strainD1210ΔthyA::KanR [F−Δ(gpt-proA)62
leuB6 supE44 ara-14 galK2 lacY1 Δ(mcrC-mrr) rpsL20 (Strr) xyl-5mtl-1
recA13 lacIq] was transformed with pMIT::TRα-1 and pMIT::TRβ-1
for growth phenotype determinations. Fresh transformant colonies
were used to inoculate 5 ml cultures of Luria-Bertani (LB) medium
supplemented with 100 μg/ml ampicillin and 50 μg/ml thymine.
These cultures were then incubated in a shaking water bath at 37 ◦C
until the OD600 of the culture reached 1.3–1.7. These cultures were
then diluted 1:200 into 50 ml of -Thy medium (per liter: 10 ml of
10% casamino acid, 10 ml of 20% glucose, 200 μL 1% thiamine HCl,
200ml of 5xMinimal Davis Broth (MDB; 35 g dipotassium phosphate,
10 g monopotassium phosphate, 2.5 g sodium citrate, 0.5 g magne-
sium sulfate and 5 g ammonium sulfate), 10 ml of Thy Pool (2 mg/
ml of each of following amino acids, L-Arg, L-His, L-Leu, L-Met, L-
Pro and L-Thr), 1 ml of 0.1 M CaCl2, pH 7.0) supplemented with 100
μg/ml ampicillin. The diluted cells where then transferred to 96 well
plates at 198 μL/well, and each well was supplemented with 2 μL
of each compound diluted in DMSO at the desired concentration. Im-
portantly, the DMSO concentration in each well was kept constant at
1% throughout each experiment, regardless of the ﬁnal ligand con-
centration. The 96 well plates were then incubated at 34 ◦C, 150 rpm
agitation and 80% humidity to assure equal volumes across the wells.
Over time, the growth of the E. coli cells in each 96 well plate was
measured by optical absorbance at a wavelength of 600 nm (OD600)
using a Biotek Synergy 2 spectrophotometer.
To conﬁrm the results of the -Thymedium test, the cells were also
grown in -Thy medium supplemented with 10 μg/mL trimethoprim
and 50 μg/mL thymine (TTM medium) and incubated at 37 ◦C. The
TTMmedium reverses the phenotype of the -Thy medium, providing
direct evidence of a speciﬁc effect of the ligand on TS activity, as
opposed to a more general ligand effect on cell growth.
2.4. Statistical analysis
The statistical signiﬁcanceof our resultswasveriﬁedbycalculating
theZ′ factor for each test asdescribedbyZhanget al. [38]. Additionally,
the signal-to-noise (S/N), and signal-to-background (S/B), ratioswere
analyzed to determine the signiﬁcance of the observed signal [39].
3. Results
3.1. Detection of agonism
The reported TR agonists Triac, T3, GC-1 and KB-141, and the neg-
ative control (E2), were each tested at a concentration of 10 μM in
the presence of the pMIT::TRα-1 and pMIT::TRβ-1 biosensor strains
(Figs. 2, 3A and B). Each well contained cells growing in -Thymedium
with a constant ﬁnal concentration of either 1% (v/v) DMSO or 1% (v/
v) DMSOwith dissolved ligand. Control experiments indicate that this
concentration of DMSO does not impact cell growth in -Thy medium,
suggesting that the use of DMSO as a delivery vehicle hasminimal im-
pact on E. coli cell viability (see Fig. S2). The time-dependent growth
of cells harboring either pMIT::TRα-1 or pMIT::TRβ-1, incubated at
34 ◦C in the presence of 10 μM T3 (in 1% DMSO) or solvent only
(1% DMSO) in -Thy medium, is presented in Supplemental Material
for the time period 15–24 h (see Figs. S1A and S1B). In all cases, the
growth rate of the biosensor cells increased in the presence of re-
ported agonists (Table 1). This result is presumably due to an increase
in TS activity upon ligand binding, and is consistent with the behavior
of our previously reported NR biosensors exposed to known agonists
(e.g., ERα and ERβ strains exposed to estrogen). A speciﬁc ligand-LBD
interaction is further supported by the observed decrease in growth
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Fig. 3. Cell growth of biosensor strains containing (A) pMIT::TRα or (B) pMIT::TRβ.
The indicated ligands were dissolved in DMSO and added at a ﬁnal concentration of
10 μM in -Thy medium at 34 ◦C (white bars), or TTM medium at 37 ◦C (grey bars),
and growth was measured after incubation for 16 h. Experiments where carried out in
triplicate, and error bars represent one standard deviation from the mean values.
Table 1
Qualitative comparison of biosensor results to previously reported activities of various
test compounds
Ligand TR biosensors Other methods Refs.
T3 Agonist Agonist [9,43]
Triac Agonist, TRβ
selective
Agonist, TRβ
selective
[2,8,41]
GC-1 Agonist, TRβ
selective
Agonist, TRβ
selective
[6,11,44]
KB-141 Agonist, TRβ
selective
Agonist, TRβ
selective
[15,16,45]
E2 (control) No signiﬁcant
effect on TRα-1.
Very weak
agonist effect
on TRβ-1
Agonist, ERα
and β. (Binding
of E2 to TRα or
β has not been
reported.)
[46]
in TTM medium in the presence of ligands. This conﬁrms that the
phenotype affects are arising speciﬁcally via the TS reporter enzyme,
and not from a more general affect of the ligand on cell growth.
Anadditional control studycompared theT3 andE2 dose responses
of the TRα-1 andTRβ-1 biosensor strains, aswell as an ERβbiosensor
strain containing pMIT::ERβ (Fig. 4). As previously reported, high TS
activitywas observedwith the ERβbiosensor strain exposed to its na-
tive estrogen ligand, E2 (Fig. 4A). In addition, E2 showed no signiﬁcant
affect on the TRα-1 biosensor (Fig. 4B), and a very slightly agonistic
activity with the TRβ-1 biosensor at high concentration (Fig. 4C). As
expected, T3 was found to be a potent agonist for both TR sensors,
Table 2
Binding and selectivity of Triac, T3, GC-1 and KB-141 for the TR bacterial biosen-
sors containing human TRα-1 and TRβ-1. Abbreviations: EC50-half maximal effective
concentration.
pMIT::TRα-1 pMIT::TRβ-1
Ligand
EC50
[μM]
EC
T3
50
EC
Ligand
50
·
100%
EC50
[μM]
EC
T3
50
EC
Ligand
50
·
100% Selectivity
T3 0.52 100.00 0.58 100.00 0.90
Triac 0.31 167.74 0.07 828.57 4.43
GC-1 0.58 89.66 0.16 362.5 4.04
KB-141 0.71 73.24 0.17 341.2 4.66
but had no agonistic effect on the ERβ biosensor. Some toxicity was
observed at high concentrations for non-interacting ligands (e.g., 100
μMT3 with pMIT::ERβ; Fig. 4A). Under these conditions, cell viability
is compromised due to thymine starvation, and very high ligand con-
centrations can lead to further decreases in cell growth. This effect is
generally not observed in cases where the ligand stimulates healthy
cell growth and high viability. Thus, to detect speciﬁc cytotoxicity of
ligands, cells are grown under non-selective conditions (in the pres-
ence of thymine) in the presence of high ligand concentrations. In
these tests, none of the tested compounds showed signiﬁcant toxicity
against our bacterial sensor strains (data not shown).
3.2. Potency and selectivity of ligands
The relative potencies of the ligands were based on dose response
determinations, where the ligand concentrations were varied by se-
rial dilution from a high concentration of 100μM(ﬁnal concentration
in the growth medium) to a low concentration where no growth af-
fect was observed (typically below 1 nM) (Fig. 5). To determine EC50
values, growth rates at various ligand concentrations were normal-
ized and ﬁtted to a standard sigmoidal dose-response equation using
nonlinear regression with variable slope (Prism ver. 5.01, GraphPad
software, San Diego, CA). Once the EC50 values had been determined
for each ligand/sensor combination, the subtype-selective binding of
the tested ligands was deﬁned as follows:
Selectivity = EC 50
L igand(T Rα)
EC 50
L igand(T Rβ)
In all cases, the results generated by our system qualitatively
matched those reported by other investigators (Table 1). For example,
in our system, the native ligand T3 showed similar EC50 values of 0.52
and 0.58μMfor TRα-1 and TRβ-1, respectively (Tables 2 and S2). The
most potent ligands for TRα-1 were Triac and T3, while KB-141 and
GC-1 were less potent and exhibited similar binding to each other.
Triac was also the most potent ligand for TRβ-1, while the GC-1 and
KB-141 potencies were 2-fold lower and T3 exhibited 8-fold lower
potency than Triac. The dose-response curves used to calculate the
EC50 values for each compound indicated that the detection limits,
which we deﬁne as the lowest concentration of a test compound that
generates an unambiguous growth signal by visual inspection, of our
TRα and TRβ biosensors for T3, KB-141 and GC-1 is approximately
100 nM, and the detection limit for Triac is approximately 10 nM (Fig.
5).
The calculated EC50 values also indicated some subtype-selective
behavior in several of the compounds. Although the native T3 ligand
showed no signiﬁcant selectivity for either TR receptor, Triac showed
higher potencywhen bound to TRβ (EC50 = 0.07μM) vs. TRα (EC50 =
0.31μM), corresponding to a selectivity ratio of 4.43 (Tables 2 and S2).
Notably, KB-141 and GC-1 were designed to bind selectively to TRβ,
and this behavior was conﬁrmed by our biosensors. Speciﬁcally, the
selectivity for TRβ over TRα was 4.04 for GC-1 and 4.66 for KB-141
(Tables 2 and S2). Further, GC-1 and KB-141were both approximately
3-fold more potent than T3 when bound to the TRβ sensor.
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Fig. 4. The effect of 17-β-estradiol (E2; white circles) and 3,5,3′-triiodo-l-thyronine
(T3; black squares) on E. coli D1210ΔthyA cells transformed with (A) pMIT::ERβ, (B)
pMIT::TRα and (C) pMIT::TRβ. The experiments were performed in -Thy medium at
34 ◦C. Experiments were carried out in triplicate, and optical densities at 600 nmwere
recorded after 24 h. Error bars represent one standard deviation from the mean for
each ligand concentration.
Several aspects of the experimental designwere examined for im-
pacts, including growth media pH and plate edge effects. These tests
indicate that the growth medium pH can lead to ﬁnal OD variations
of up to 25% over the range pH 6.9–7.1 (data not shown), and there-
fore great care was taken to adjust the growth media pH to precisely
7.0 during all experiments. Edge variations on the 96-well microtiter
plates were as high as 10% in cases where cell growth levels are low,
Fig. 5. Growth response and subtype-selectivity of tested compounds using the
pMIT::TRα and pMIT::TRβ biosensors. For dose-response determinations, E. coli
D1210ΔthyA cells harboring each biosensor plasmid were incubated in -Thy medium
in the presence of the indicated compound at 34 ◦C. Experiments were carried out in
triplicate, and optical densities at 600 nmwere recorded after 16 h. Error bars represent
one standard deviation from the mean for each ligand concentration. (a) T3, (b) Triac,
(c) GC-1, (d) KB-141.
Table 3
Statistical analysis of the TR biosensor responses derived from three separate 96-well
plates with three dose-response tests on each plate (nine total tests). Abbreviations:
S/N-signal-to-noise ratio; S/B-signal-to-background ratio; Z′ factor-determines the
statistical quality of the test as described by Zhang et al. [38].
pMIT::TRα-1 pMIT::TRβ-1
Ligand S/N S/B Z′ S/N S/B Z′
T3 66.88 3.52 0.76 16.59 3.48 0.66
Triac 89.55 4.37 0.71 18.71 3.80 0.79
GC-1 72.75 4.02 0.79 46.35 3.92 0.91
KB-
141
74.62 4.10 0.85 46.01 3.89 0.92
but were limited to approximately 4% at higher growth levels (data
not shown). To minimize these systematic errors, each dose response
series was carried out in triplicate on each plate, and results from
three separate plates were used to calculate the ﬁnal values for EC50.
To verify the ability of our sensor to report a statistically signiﬁcant
result for each test ligand, Z′ factors were calculated using the aver-
ages and standard deviations of the measured growth values at the
highest and lowest concentrations of each ligand tested. This analy-
sis yielded Z′ factors greater than 0.5 for all of our tests, indicating
that the biosensor response to each of the tested compounds was un-
ambiguously signiﬁcant (Table 3). Further, all of the S/N ratios were
above 66 for TRα and 16 for TRβ, while the S/B ratiowas consistently
above 3 for both biosensors.
4. Discussion
The ﬁrst subtype-selective thyromimetics have appeared during
the last 10 years [11]. In conventional transcriptional activation as-
says, the potency and selectivity (TRα/TRβ) of ligands can vary de-
pending on the co-regulators present, which typically include SRC1–
2, SRC3–2 and NCoR1–2 [19,40]. Other factors can also inﬂuence
outcomes, such as the in vivo or in vitro method type, the physico-
chemical characteristics of the compounds, and the type of solvents
252 Izabela Gierach et al. / FEBS Open Bio 2 (2012) 247–253
used,whichmay enhance ligandpenetration through cellmembranes
depending on the assay. Despite the large variety of assays available,
there is a need for comparable qualitative and quantitative data for
evaluating thyromimetic TR-subtype-selectivity [41].
These biosensors provide an alterative method to mammalian
cell reporter gene assays for characterizing potency and isoform-
selectivity of ligands. Although the results obtained from this biosen-
sor method follow the qualitative trends observed in conventional
in vitro studies, the sensitivity of the bacterial sensors is currently
lower. For example, the native thyroid hormone T3 has been shown
to bind both TRα and TRβ with similar afﬁnity (Kd = 0.1 nM) and
potency (EC50 = 2 nM), as determined via binding and transcriptional
activation assays [21]. Our system reproduced the qualitative aspects
of these results, indicating non-selective binding of T3 to the TR re-
ceptors, but yielded much lower apparent potencies in the context of
the biosensor assay (potencies of 0.52 μM and 0.58 μM for TRα and
TRβ, respectively).
In all cases, however, our biosensor system qualitatively repro-
duced important therapeutically relevant characteristics of the con-
trol ligands, including binding afﬁnity relative to T3 and subtype-
selective binding. For example, in one previous study, Triac was re-
ported to have 6-fold higher potency than T3 when binding to TRβ
[8], while in another, Triac was found to have approximately 3-fold
higher afﬁnity than T3 for TRβ and identical afﬁnity to T3 for TRα [7].
Those subtype-selective differences are consistent with the relative
potencies obtained in ourwork,where Triacwas observed to be 8-fold
more potent than T3 against TRβ, and 1.7 timesmore potent for TRα.
The in vitro afﬁnity of GC-1 for the TR subtypes has also been studied
previously, where it showed stronger binding to TRβ (Kd of 0.1±0.02
nM) than TRα (Kd of 1.8±0.2 nM) [4]. Chiellini et al. also reported
EC50 values for GC-1 using a transcriptional activation assay, which
again indicated preferential binding of GC-1 to TRβ (7 nM vs. 45 nM
for TRα) [4]. These results are quantitatively similar to our results
in terms of subtype-selectivity, although our actual EC50 values are
3-fold different (0.2μMvs. 0.6μM for TRβ and TRα, respectively). In
additional previous work on KB-141, an in vitro radioactive displace-
ment assay indicated a 10-fold TRβ binding selectivity for KB-141,
while an in vivo transactivation assay conﬁrmed the agonistic behav-
ior of KB-141 and indicated an 8-fold greater binding afﬁnity for TRβ
when normalized to T3 [15]. In our study, GC-1 and KB-141 were re-
spectively observed to be approximately 4- and 4.7-fold selective for
TRβ over TRα.
Although our calculated EC50 values are substantially higher than
those determined from previous in vitro binding and transactivation
assays, our results are qualitatively consistent with these assays in
terms of agonistic behaviors and relative potencies. The differences
in EC50 between our and other assays likely arise from the non-
transcriptional nature of the assay, and its reliance on membrane
diffusion in bacterial cells. Further, the EC50 values exhibited by our
system are reasonable for the detection of therapeutically relevant
compounds (e.g., T3, GC-1 and KB-141). These compounds typically
must have nanomolar binding afﬁnities in order to exhibit a reason-
able therapeutic index. Since our assay can tolerate concentrations
several orders of magnitude above this, it can be used to detect the
activity of these compounds up to their solubility limits. Since these
limits are typically greater than 10μM,we feel that the testable range
of concentrations is adequate for initial library screening. The calcu-
lated EC50 values can then be benchmarked against the standard com-
pounds described in this work. Importantly, our overall results were
obtained with excellent reproducibility and robust statistical signif-
icance, with Z′ factors between 0.92 and 0.66. Finally, the signal-to-
noise and background measurements were also excellent, and were
indicative of very clear results (90>S/N>66 and4.5>S/B>3.5 for TRα
and 46.5>S/N> 16.5 and 4>S/B>3.4 for TRβ).
In previous studies, compounds with low afﬁnity were also char-
acterized using similarly engineered ER β biosensors. The relative
binding afﬁnity (RBA = EC
Estradiol
50
EC
Ligand
50
× 100%) of bisphenol A for human
ER β biosensor was reported as 1.15% (relative to 100% for 17-β-
estradiol), whereas for porcine ERβ biosensor only 0.13% [39]. How-
ever, we have not determined the minimum detectable afﬁnity for
thyromimetics, and this is planned for future work with a greater
variety of compounds.
Our thyroid hormone biosensors provide a means to identify TR
agonists anddetermine relative EC50 values across a variety of ligands,
which allows identiﬁcation of subtype-selective compounds within
large chemical libraries. Further, methods based on these biosensors
are both simple and economical, and these approaches have shown
utility in the discovery of subtype-selective compounds for ERα and
ERβ [33,34,42].
It is therefore possible that these biosensors will become an im-
portant primary screen for TR-selective compounds that might be
used to treat a wide range of metabolic disorders.
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